Observation of the Clinical Efficacy of Metformin and Pioglitazone in the Treatment of Type 2 Diabetes Mellitus Complicated with Coronary Heart Disease
Elias Abula （ Department of Endocrinology, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi Province, China ）
Shan Gao （ Department of Endocrinology, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi Province, China ）
https://doi.org/10.37155/2717-5278-0601-1Abstract
Objective: To analyze the application effects of metformin and pioglitazone in the treatment of type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD). Methods: A total of 82 patients with T2DM and CHD from November 2022 to November 2023 were selected for the study. Using a random number table, they were evenly divided into a control group (41 cases treated with pioglitazone) and an observation group (41 cases treated with a combination of metformin and pioglitazone). The clinical efficacy of the two groups was compared. Results: The incidence of adverse reactions in both groups was basically the same (P＞0.05); the observation group showed significantly lower rates of complications, fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), glycated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol (TC), triglycerides (TG), and Gensini score than the control group (P＜0.05). Conclusion: Compared with monotherapy, the combined use of pioglitazone and metformin can enhance the clinical efficacy in treating T2DM complicated with CHD, regulate lipid indicators, and has potential for promotion.
Keywords
Metformin; Pioglitazone; Type 2 diabetes mellitus; Coronary heart diseaseFull Text
PDFReferences
[2] Cai Junling. Application advantages of liraglutide combined with metformin in the clinical treatment of type 2 diabetes complicated with coronary heart disease [J]. Diabetes New World, 2023, 26(12):81-84.
[3] Kang Jie, Zhang Jianjian, Zhang Weidong, Zhang Yue, Huang Gaode. Observation on the efficacy and safety of nicorandil combined with metformin in the treatment of patients with type 2 diabetes and coronary heart disease [J]. International Medical and Health Herald, 2023, 29( 7):936-939.
[4] Li Wenzheng. Evaluation of the clinical effect of liraglutide combined with metformin in the treatment of type 2 diabetes complicated with coronary heart disease [J]. Diabetes New World, 2023, 26(7):80-83.
[5] Yu Ruihua. Analysis of the effectiveness of metformin plus insulin glutathione in the treatment of type 2 diabetes complicated with coronary heart disease [J]. Diabetes New World, 2023, 26(7):99-102.
[6] Sun Xiaodong, Mo Yuhua, Han Lu. Analysis of the clinical effect of metformin and pioglitazone in the treatment of type 2 diabetes complicated with coronary heart disease [J]. Diabetes New World, 2023, 26(6): 65-68.
[7] Chen Yan, Wang Hao, Wei Xueli. Effects of acarbose combined with metformin on glucose metabolism, inflammatory factors and cardiovascular events in patients with type 2 diabetes and coronary heart disease [J]. Journal of Chronic Diseases, 2023, 24(2): 315-317.
[8] Wei Dayong. Effect of metformin hydrochloride and dapagliflozin in the treatment of elderly patients with type 2 diabetes and coronary heart disease [J]. Diabetes New World, 2022, 25(17):91-93+97.
[9] Guo Jianping, Wei Qin, Peng Danping, Yan Dien, Xiao Liming, Zhou Xiaozhi, Wang Meili, Zheng Huanhuan, Fu Jinxiang, Liu Jinping, Xiao Weiping. Alogliptin combined with metformin and glimepiride on elderly patients with type 2 diabetes and coronary heart disease Comparison of the effects of blood sugar fluctuations[J]. Journal of Rational Clinical Drug Use, 2022, 15(24):53-56.
[10] Zhao Xiaotao, Sun Ying. Analysis of the clinical effect of metformin and pioglitazone in the treatment of type 2 diabetes complicated with coronary heart disease [J]. Practical Clinical Integration of Traditional Chinese and Western Medicine, 2021, 21(17): 25-26.
Copyright © 2024 Elias Abula, Shan Gao
Publishing time:2024-01-23
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location